公开(公告)号：US11147792B2

公开(公告)日：2021-10-19

申请号：US16611406

申请日：2018-05-14

申请人： Axial Therapeutics, Inc ,  California Institute of Technology

发明人： Timothy Sampson ,  Sarkis Mazmanian ,  Anthony Stewart Campbell

IPC分类号： A61K31/353 ,  A61P25/28 ,  A61P25/16 ,  A61K31/05 ,  A61K31/192 ,  A61K31/216 ,  A61K31/235 ,  A61K31/465 ,  A61K31/522 ,  A61K45/06

摘要： The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.

公开(公告)号：US11136340B2

公开(公告)日：2021-10-05

申请号：US16526219

申请日：2019-07-30

申请人： AstraZeneca AB

发明人： Maurice Raymond Verschoyle Finlay ,  Frederick Woolf Goldberg ,  Attilla Kuan Tsuei Ting

IPC分类号： A61K31/522 ,  A61P35/00 ,  C07D519/00 ,  C07D473/18 ,  A61K31/502 ,  A61K45/06

摘要： The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

公开(公告)号：US11129834B2

公开(公告)日：2021-09-28

申请号：US16541490

申请日：2019-08-15

申请人： Novira Therapeutics, Inc. ,  Janssen Sciences Ireland Unlimited Company

发明人： George Hartman ,  Osvaldo Flores ,  Klaus Klumpp ,  Man Iu Lam ,  Jan Martin Berke

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/52 ,  A61K31/40 ,  A61K31/445 ,  A61K31/522 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/03 ,  A61K31/095 ,  A61K31/18 ,  A61K31/706 ,  C12N7/06

摘要： The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.

公开(公告)号：US11129811B2

公开(公告)日：2021-09-28

申请号：US16508883

申请日：2019-07-11

申请人： Patrick Ketter ,  Bernard Arulanandam ,  M. Neal Guentzel

发明人： Patrick Ketter ,  Bernard Arulanandam ,  M. Neal Guentzel

IPC分类号： A61K31/4164 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/428 ,  A61K31/437 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5415

摘要： Certain embodiments are directed to methods and compositions for preventing or treating bacterial infections. In certain embodiments the compositions comprise thioredoxin inhibitors, and/or thioredoxin-like inhibitors.

公开(公告)号：US20210290626A1

公开(公告)日：2021-09-23

申请号：US17120217

申请日：2020-12-13

申请人： Matthew H. Kopacki ,  Michael J. Torsiello

发明人： Matthew H. Kopacki ,  Michael J. Torsiello

IPC分类号： A61K31/522 ,  A61K31/4418 ,  A61K31/517 ,  A61K31/506 ,  A61K45/06 ,  A61K31/44 ,  A61K31/52

摘要： A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof.

公开(公告)号：US11123323B2

公开(公告)日：2021-09-21

申请号：US15211046

申请日：2016-07-15

申请人： Maria Clemetine Martin Klosterfrau Vertriebsqesellschaft MBH

发明人： Harald Greve

IPC分类号： A61K31/352 ,  A61P11/06 ,  A61K31/35 ,  A61K31/045 ,  A61K45/06 ,  A61K31/137 ,  A61K31/573 ,  A61K9/48 ,  A61K9/00 ,  A61K31/522

摘要： The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).

公开(公告)号：US11123279B2

公开(公告)日：2021-09-21

申请号：US16070590

申请日：2017-01-19

申请人： AchromaZ Pte. Ltd.

发明人： Peter Samuel James Cheetham ,  Christoph Langwallner ,  Margit Langwallner ,  Wen Jue Amelia Tan

IPC分类号： A61K8/49 ,  A61Q19/02 ,  A61Q19/08 ,  A61K8/55 ,  A61K31/708 ,  A61K31/52 ,  A61K31/351 ,  A61K31/341 ,  A61K31/216 ,  A61K31/192 ,  A61K31/425 ,  A61K31/222 ,  A61K31/194 ,  A61K31/54 ,  A61K31/4035 ,  A61K31/12 ,  A61K31/536 ,  A61K31/166 ,  A61K31/513 ,  A61K31/343 ,  A61K31/122 ,  A61K31/215 ,  A61K31/522 ,  A61K31/4412 ,  A61K8/9728

摘要： The present invention relates to cosmetic or personal care compositions comprising two or more compounds, each compound containing an allylic or partially allylic carbonylsubstructure having the following structure I: wherein Y is a second substructure immediately adjacent to the allylic or partially allyliccarbonyl substructure and is selected from one of the following groups consisting of (i) hydroxyl-based group including —OH or —C(═)—(OH); (ii)carbonyl-based group including —C(═)—C (═O)—CH3; (iii) N ether group, —O—; (iv) sultam group, —N(H)—S(═O)2—; (v) lactam group, —N(H)—C(═O)—; (vi) apolar group including cyclic structures based on menthol or carotenoids; (vii) secondary aldimine containing group including —N(H)—C(NH2)═N— or —N(H)—C(H)═N—; (viii) amine group, —NH2; (ix) secondary amine-based group, —N(H)—; and (x) amide-based group including —N(H)—C(═O)— or —N(H)—C(═O)—N(H)—, their derivatives, isomers, salts and/or combination thereof; and a cosmetically acceptable vehicle.

公开(公告)号：US20210283070A1

公开(公告)日：2021-09-16

申请号：US17199903

申请日：2021-03-12

申请人： Sovereignty

发明人： Jason Crawford

IPC分类号： A61K31/05 ,  A61K36/81 ,  A61K36/68 ,  A61K36/185 ,  A61K36/82 ,  A61K36/74 ,  A61K36/736 ,  A61K36/45 ,  A61K36/31 ,  A61K36/9066 ,  A61K31/522 ,  A61K36/79 ,  A61K31/4045 ,  A61K31/198 ,  A61K36/21 ,  A61K31/197 ,  A61K36/53 ,  A61K45/06

摘要： A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

公开(公告)号：US20210275513A1

公开(公告)日：2021-09-09

申请号：US16343083

申请日：2017-04-12

申请人： CONARIS RESEARCH INSTITUTE AG ,  CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL

发明人： Karin SCHWARZ ,  Julia KEPPLER ,  Eva-Maria THEISMANN ,  Jörg KNIPP ,  Daniela FANGMANN ,  Matthias LAUDES ,  Stefan SCHREIBER ,  Georg WÄTZIG

IPC分类号： A61K31/455 ,  A61K9/50 ,  A61K9/48 ,  A61K9/00 ,  A61K31/522 ,  A61K31/573 ,  A61K35/741 ,  A61K31/616 ,  A61K45/06 ,  A23L33/15 ,  A23L33/16 ,  A23L33/00 ,  A23L33/135 ,  A23P20/10

摘要： The present invention relates to microcapsules comprising a core containing vitamin B3, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.

公开(公告)号：US11102994B2

公开(公告)日：2021-08-31

申请号：US14678846

申请日：2015-04-03

申请人： ClearFast Inc.

发明人： M. Lou Marsh

IPC分类号： A23L2/52 ,  A23L2/68 ,  A23L2/60 ,  A61K45/06 ,  A61K47/26 ,  A61K9/08 ,  A61K31/07 ,  A61K31/198 ,  A61K9/00 ,  A61K31/522

摘要： Provided herein are beverage compositions to be ingested by a patient prior to administration of anesthesia or sedation comprising: a) one or more carbohydrates, wherein the total Calories available from the carbohydrates is at least about 200 and wherein the one or more carbohydrates are the sole source of significant Calories in the beverage; b) an acid, in a quantity sufficient to result in a pH of at least about 3.7 to about 4.5 and to enhance the shelf life and flavor of the beverage; c) a central nervous system (CNS) stimulant that is also a cerebro-vasoconstrictor; d) a sweetener and e) water, wherein the beverage composition, when ingested at least about two hours prior to administration of anesthesia or sedation is effective to relieve one or more symptoms associated with prolonged fasting. Further provided herein are methods of using the pre-operative beverage compositions disclosed herein in preparation for the safe induction of anesthesia or sedation in a patient before surgery.